Enterprise Value
-8.049M
Cash
85.54M
Avg Qtr Burn
N/A
Short % of Float
4.70%
Insider Ownership
1.40%
Institutional Own.
48.86%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Brexafemme (Ibrexafungerp) Details Vulvovaginal Candidiasis, Yeast Infection | Approved Quarterly sales | |
Brexafemme (Ibrexafungerp) Details Fungal infections | Approved Quarterly sales |